OBJECTIVE: A study was conducted to define the natural history and disease progression of HIV infection in a developing country. DESIGN: A prospective longitudinal cohort study. METHODS: Forty-two patients with documented dates of HIV seroconversion were followed in Port-au-Prince, Haiti. Patients were seen at 3 month intervals or when ill. Patients were treated for bacterial, mycobacterial, parasitic, and fungal infections, but antiretroviral therapy was not available. Patients were followed until death or until 1 January 2000; median follow-up was 66 months. RESULTS: By Kaplan-Meier analyses, the median time to symptomatic HIV disease (CDC category B or C) was 3.0 years [95% confidence interval (CI) 2.3-5.0 years]. The median time to AIDS (CDC category C) was 5.2 years (95% CI 4.7-6.5 years), and the median time to death was 7.4 years (95% CI 6.2-10.2 years). Community-acquired infections, including respiratory tract infections, acute diarrhea, and skin infections were common in the pre-AIDS period. AIDS-defining illnesses included tuberculosis, wasting syndrome, cryptosporidiosis, cyclosporiasis, candida esophagitis, toxoplasmosis, and cryptococcal meningitis. Rapid progression to death was associated with anemia at the time of seroconversion hazards ratio (HR) 4.1 (95% CI 1.1-15.0), age greater than 35 years at seroconversion HR 4.4 (95% CI 1.1-16.6), and lymphopenia at seroconversion HR 11.0 (95% CI 2.3-53.0). CONCLUSION: This report documents rapid disease progression from HIV seroconversion until death among patients living in a developing country. Interventions, including nutritional support and prophylaxis of common community-acquired infections during the pre-AIDS period may slow disease progression and prolong life for HIV-infected individuals in less-developed countries.
OBJECTIVE: A study was conducted to define the natural history and disease progression of HIV infection in a developing country. DESIGN: A prospective longitudinal cohort study. METHODS: Forty-two patients with documented dates of HIV seroconversion were followed in Port-au-Prince, Haiti. Patients were seen at 3 month intervals or when ill. Patients were treated for bacterial, mycobacterial, parasitic, and fungal infections, but antiretroviral therapy was not available. Patients were followed until death or until 1 January 2000; median follow-up was 66 months. RESULTS: By Kaplan-Meier analyses, the median time to symptomatic HIV disease (CDC category B or C) was 3.0 years [95% confidence interval (CI) 2.3-5.0 years]. The median time to AIDS (CDC category C) was 5.2 years (95% CI 4.7-6.5 years), and the median time to death was 7.4 years (95% CI 6.2-10.2 years). Community-acquired infections, including respiratory tract infections, acute diarrhea, and skin infections were common in the pre-AIDS period. AIDS-defining illnesses included tuberculosis, wasting syndrome, cryptosporidiosis, cyclosporiasis, candida esophagitis, toxoplasmosis, and cryptococcal meningitis. Rapid progression to death was associated with anemia at the time of seroconversion hazards ratio (HR) 4.1 (95% CI 1.1-15.0), age greater than 35 years at seroconversion HR 4.4 (95% CI 1.1-16.6), and lymphopenia at seroconversion HR 11.0 (95% CI 2.3-53.0). CONCLUSION: This report documents rapid disease progression from HIV seroconversion until death among patients living in a developing country. Interventions, including nutritional support and prophylaxis of common community-acquired infections during the pre-AIDS period may slow disease progression and prolong life for HIV-infected individuals in less-developed countries.
Authors: Michael Worobey; Arthur E Pitchenik; M Thomas P Gilbert; Gabriela Wlasiuk; Andrew Rambaut Journal: Proc Natl Acad Sci U S A Date: 2008-03-12 Impact factor: 11.205
Authors: Jean William Pape; Paul Farmer; Serena Koenig; Daniel Fitzgerald; Peter Wright; Warren Johnson Journal: Proc Natl Acad Sci U S A Date: 2008-03-06 Impact factor: 11.205
Authors: Jean W Pape; Patrice D Severe; Daniel W Fitzgerald; Marie M Deschamps; Patrice Joseph; Cynthia Riviere; Vanessa Rouzier; Warren D Johnson Journal: J Acquir Immune Defic Syndr Date: 2014-01-01 Impact factor: 3.731
Authors: E M Gaillard; L-M Boulos; M P André Cayemittes; L Eustache; J D Van Onacker; N Duval; E Louissaint; G Thimoté Journal: Sex Transm Infect Date: 2006-04 Impact factor: 3.519
Authors: Macarthur Charles; Francine Noel; Paul Leger; Patrice Severe; Cynthia Riviere; Carole Anne Beauharnais; Erica Miller; John Rutledge; Heejung Bang; Wesley Shealey; Richard T D'Aquila; Roy M Gulick; Warren D Johnson; Peter F Wright; Jean William Pape; Daniel W Fitzgerald Journal: Bull World Health Organ Date: 2008-12 Impact factor: 9.408
Authors: April D Kimmel; Macarthur Charles; Marie-Marcelle Deschamps; Patrice Severe; Alison M Edwards; Warren D Johnson; Daniel W Fitzgerald; Jean W Pape; Bruce R Schackman Journal: J Acquir Immune Defic Syndr Date: 2013-06-01 Impact factor: 3.731